Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Con...
August 13 2018 - 2:00AM
Press Release
13 August 2018
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in
Combination with CPIs and Immune Enhancers at ESMO 2018 Congress
Immunicum AB
(publ; IMMU.ST) announced today that the company will present a
poster on its lead development candidate, ilixadencel, at the
European Society for Medical Oncology (ESMO)
2018 Congress, held October 19-23, 2018 in Munich,
Germany. Immunicum will announce the complete data through a press
release following the presentation. The poster abstract will also
be published in the ESMO 2018 Congress Abstract Book, a supplement
to the official ESMO journal, Annals of Oncology.
Poster
Information:
Title:
Intratumoral administration of pro-inflammatory allogeneic,
"off-the-shelf", dendritic cells in combination with anti-PD-1 or
anti-CD137 has a synergistic anti-tumor effect
Presentation Number: 440P
Presenter: Dr. Alex Karlsson-Parra, Chief
Scientific Officer
Date & Time: Monday, October 22, 2018;
12.45 - 13.45 CET
Location: Hall A3 - Poster Area Networking
Hub
About
ilixadencel
Ilixadencel, a cell therapy product, is an off-the-shelf cancer
immune primer, developed for the treatment of solid tumors. Its
active ingredient is activated allogeneic dendritic cells, derived
from healthy blood donors. Intratumoral injection of these cells
generates an inflammatory response which in turn leads to
tumor-specific activation of the patient's cytotoxic T-cells.
For more information, please contact:
Carlos de Sousa, CEO,
Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Michaela Gertz, CFO,
Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com
Media Relations
Gretchen Schweitzer and Joanne
Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com
About Immunicum AB (publ)
Immunicum is establishing a unique
immuno-oncology approach through the development of allogeneic,
off-the-shelf cell-based therapies. Our goal is to improve survival
outcomes and quality of life by priming the patient's own immune
system to fight cancer. The company's lead product ilixadencel,
consisting of pro-inflammatory allogeneic dendritic cells, has the
potential to become a backbone component of modern cancer
combination treatments in a variety of solid tumor indications.
Founded and based in Sweden, Immunicum is publicly traded on the
Nasdaq Stockholm. www.immunicum.com
20180813_Immunicum_ESMO poster
acceptance_Final ENG
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Sep 2023 to Sep 2024